By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Avila Therapeutics 

100 Beaver Street

Waltham  Massachusetts    U.S.A.
Phone: 781-891-0086 Fax: 781-891-0069



Company News
Genome-Editing Company Editas Medicine Brings In Ex-Avila Therapeutics CEO For Top Post 6/24/2014 6:15:51 AM
Celgene Corporation (CELG) Completes Acquisition of Avila Therapeutics 3/8/2012 6:47:19 AM
Celgene (CELG) Acquisition of The Leukemia & Lymphoma Society Partner, Avila Therapeutics, Significant Advance for Novel Blood Cancer Therapy 1/27/2012 10:59:41 AM
Celgene (CELG) to Acquire Avila Therapeutics for Up to $925 Million 1/26/2012 7:10:22 AM
Avila Therapeutics Announces FDA Allowance of Partner Clovis Oncology (CLVS)’s IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor, Triggers $4 Million Milestone Payment to Avila 1/20/2012 7:17:05 AM
Avila Therapeutics to Present at J.P. Morgan Healthcare Conference 1/3/2012 6:56:45 AM
Avila Therapeutics Presents Data on AVL-292, a Selective Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of B Cell Cancers at the 2011 American Society of Hematology Annual Meeting 12/12/2011 11:10:23 AM
Avila Therapeutics to Present at the 2011American Society of Hematology Annual Meeting 12/5/2011 6:28:14 AM
Avila Therapeutics Presents Clinical and Preclinical Data on AVL-292 Showing Potential for the Treatment of Autoimmune Disease at the 2011 American College of Rheumatology Annual Scientific Meeting 11/8/2011 7:21:05 AM
Avila Therapeutics to Present at Lazard Capital Markets 8th Annual Healthcare Conference 11/7/2011 4:21:42 PM